WE COLLABORATE TO INNOVATE
Here at ViiV Healthcare, we encourage collaborations with pharmaceutical and biotechnology companies, individuals, academic institutions and not-for-profit organisations in the healthcare community in order to broaden our capability and enhance our performance still further.
Here at ViiV Healthcare, we encourage collaborations with pharmaceutical and biotechnology companies, individuals, academic institutions and not-for-profit organizations in the healthcare community in order to broaden our capability and enhance our performance still further.
We recognize that in spite of recent scientific advances there are still many gaps in our knowledge and understanding of how best to prevent, treat and ultimately cure HIV. Only by working together with other members of the community will we be able to respond to the demands of a rapidly evolving epidemic.
Examples of how we collaborate to innovate include:
- Our R&D team's close collaboration with scientists at Shionogi which resulted in the joint discovery of a portfolio of novel integrase inhibitors. Find out more about our medicines in development.
- Our first-of-its-kind public-private partnership with the Clinton Health Access Initiative (CHAI) and Mylan Laboratories Ltd to submit a registration for a new taste-masked dispersible HIV medicine for children living in the world's poorest countries. Read the press release
- Our membership of the International AIDS Societies Towards an HIV Cure Industry Collaborative Group and the Collaboration for HIV/AIDS Immunological Therapy (CHAIT), a public-private partnership launched in 2012 to focus on the development of novel immunological therapeutic interventions to achieve a functional HIV cure with the ultimate goal of HIV eradication.
In addition to our own pipeline, we also seek to in-partner patent protected competitive compounds (discovery stage through to marketed products) that will have a positive impact on the lives of people living with HIV/AIDS. We are especially interested in clinical stage assets that have the potential to deliver a significantly differentiated product profile versus currently marketed HIV therapies.
We will consider various business arrangements including option based collaborations, standard licensing agreements, company acquisitions
For further information please contact:
Dr. Trevor Scott
Vice President and Head, Business Development and Alliances
5 Moore Drive, Research Triangle Park, North Carolina 27709-3398, USA.
Tel. +1 919 483-8215
Fax + 1 919 315-0027